About this trial
The goal of this clinical trial is to learn if the drug naloxone in addition to cardiopulmonary resuscitation improves outcomes of in-hospital cardiac arrets. The main questions it aims to answer are:
Does naloxone improve survival after the cardiac arrest? Does naloxone improve functional outcome in survivors of cardiac arrest? Does naloxone improve health related quality of life after the cardiac arrest? How common are adverse reactions to naloxone when administered during cardiopulmonary resuscitation.
Researchers will compare naloxone to a placebo (a look-alike substance that contains no drug) to see if naloxone works during cardiac arrest.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
In-Hospital Cardiac Arrest
Age ≥ 18 years
Received at least one dose of adrenaline during CPR
Disqualifiers
"Do-not-resuscitate"-order
Known/suspected pregnancy
Known objection by the patient to participate in the trial
Previous inclusion in the trial
Trial design
Parallel
Treatments tested in this trial
naloxone
Drug2 mg naloxone administered intravenously or intraosseously
Placebo
Drug0.9% saline administered intravenously or intraosseously
Treatment groups
Trial outcomes
Primary outcomes
30-day survival
proportion of patients alive
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Region Skane
Lead sponsor
Lund University
Collaborator
Clinical Studies Sweden - Forum South
Collaborator
Copenhagen Trial Unit, Center for Clinical Intervention Research
Collaborator
This trial is not recruiting at the moment. You can still explore other options: